Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated.

ELLENCE is indicated for use in adjuvant therapy of breast cancer patients with evidence of axillary lymph node involvement following surgery.

100–120 mg/m² IV bolus, repeated every 3–4 weeks.

Administer either:

• Entire dose on Day 1, or

  • Split between Days 1 and 8.

Common (≥10%):

Hematologic: Neutropenia, leukopenia, anemia, thrombocytopenia

GI: Nausea/vomiting, mucositis, diarrhea

Other: Alopecia, amenorrhea, fatigue, infection

• Severe cardiac conditions
• Recent myocardial infarction
• Persistent myelosuppression
• Severe hepatic impairment
• Hypersensitivity to anthracyclines

Cardiac Function: Perform baseline ECG and LVEF assessment.

Secondary Malignancies: Increased long-term leukemia risk.

Extravasation Management: Discontinue immediately, apply ice, consider dexrazoxane.

Myelosuppression: Monitor CBC before each cycle.

Hepatic/Renal Impairment: Adjust dose or avoid use in severe cases.

Tumor Lysis Syndrome, Immunosuppression, Thromboembolism, Radiation recall, Embryo-fetal toxicity